Dxcover is at the forefront of developing a multi-cancer detection platform that leverages advanced artificial intelligence and innovative hardware to facilitate early diagnosis of various cancers, with a particular focus on brain tumors. The Dxcover Platform utilizes a unique approach that involves analyzing a patient's blood serum through infrared spectroscopy. This method allows for the rapid detection of disease presence or absence by capturing vital data from the body's response to potential malignancies. The integration of AI algorithms enhances the diagnostic process, providing results in a matter of minutes, which is crucial for improving patient outcomes.

The company has successfully completed significant clinical studies that validate its technology, demonstrating its potential to revolutionize cancer diagnostics. By focusing on liquid biopsies, Dxcover aims to improve the early detection of cancers, thereby increasing survival rates and enhancing the quality of life for patients. The platform's design is rooted in cutting-edge research and has garnered recognition for its scientific excellence, positioning Dxcover as a leader in the field of cancer diagnostics and liquid biopsy technology.

United Kingdom

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA. 

Dxcover

Company Details